Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Related REGN
UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts
UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence
Making Money With Charles Payne: 10/31/14 (Fox Business)
Related AGN
#PreMarket Primer: Friday, November 21: Immigration Reform Could Have Lasting Impact In More Ways Than One
Can The Uptrend Continue For Allergan?
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Nov 2014Bank of AmericaMaintainsBuy
Nov 2014Brean CapitalMaintainsBuy
Nov 2014Argus ResearchMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters